Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Galectin Therapeutics reported a net loss of $17.7 million for the nine months ended September 30, 2026, an improvement from the $25.3 million loss in the prior year period. A significant balance sheet event occurred with the conversion of $105.2 million in debt into common stock, substantially reducing total liabilities and increasing the common shares outstanding to over 100 million.
Tyson Foods reported 2026 sales of $56.4 billion, a 3.6% increase driven by higher average sales prices and an additional fiscal week. Despite sales growth, net income attributable to Tyson decreased slightly to $453 million, impacted by significant restructuring charges, legal contingency accruals, and continued operating losses in the Beef segment.
Montauk Renewables reported Q3 2026 revenues of $50.2 million, a 10.9% increase year-over-year, though net income fell 58.9% to $2.1 million. The company announced it has executed a non-binding term sheet to amend its credit facility to borrow additional debt and address liquidity concerns, avoiding a previously anticipated going concern qualification. Additionally, the company plans to invest $15.0 million in enhancements at its Turkey, North Carolina facility to address feedstock moisture and syngas temperature issues limiting commercial production.
Creative Realities reported Q3 2026 revenue of $26.2 million, a significant increase from $10.5 million in the prior-year period, driven by the acquisition of Cineplex Digital Media and new contract wins. The company reported Adjusted EBITDA of $2.7 million and annualized recurring revenue (ARR) of $21.7 million. Management expects full-year 2026 revenue to exceed $100 million, supported by retail media deployments and stadium installations.
Term
Q3 2026
“We continue to set new records this year in terms of growth acceleration, business wins, and EBITDA expansion. We anticipate revenue exceeding $100 million in fiscal 2026, as the fourth quarter is expected to benefit from seasonal factors related to our retail media contracts as well as from the positive impact of recent awards and new customer installations.”
Rick Mills, Chief Executive Officer
“We focused on the balance sheet this quarter, using existing cash to pay down debt, provide increased financial flexibility, and reduce ongoing interest expense. Our talented staff and leadership successfully executed an operating strategy that is producing significant growth as we become a more nimble organization intent on achieving improved bottom line results and cash generation.”
Tyson Foods reported fourth quarter and fiscal year 2026 results, with annual sales increasing 3.6% to $56.4 billion. While GAAP operating income remained flat at $1.1 billion, adjusted EPS for the full year declined 17% to $3.44, reflecting a challenging operating environment despite growth in Prepared Foods and resilience in the Chicken segment.
“Our performance in fiscal 2026 reflects the strength of our diversified multiprotein model and our dedication to our customers and consumers. We’ll build on those strengths through investment in our brands, innovation and operating capabilities, while remaining focused on the returns those investments can deliver alongside market conditions.”
Jeff Schomburger, President and CEO of Tyson Foods
Edible Garden reported third quarter 2026 financial results, featuring a 14% revenue increase to $3.2 million and a significant gross margin expansion to 23.9%. The company highlighted strong growth in cut herb sales and secured a major private-label RTD protein beverage award from a large grocery retailer. Management noted that these improvements were achieved during the company's seasonally slowest quarter.
Term
Q3 2026
“Our third-quarter results reflect meaningful progress in strengthening our business.”
Jim Kras, Chief Executive Officer of Edible Garden
VIDA Global reported Q3 2026 financial results with revenue increasing 88% year-over-year to $0.33 million. The company highlighted the transition of its computer agents out of beta and the expansion of its go-to-market team and partnerships with ALLO Fiber and AVANT.
Term
Q3 2026
“In the third quarter, we believe we put the foundation in place to scale Vida’s AI workforce. Our computer agents came out of beta, so Vida’s AI employees now have the ability to do the work behind the conversation, not just the conversation. We built outcome-based billing, expanded our sales team, and signed partners including ALLO Fiber and AVANT.”
Agape ATP Corp reported a significant decline in revenue to $40,079 for the nine months ended September 30, 2026, compared to $352,844 in the prior year. Despite the revenue drop, the net loss narrowed to $275,153 from $1,931,535, primarily due to a substantial $1.3 million foreign exchange gain and income from the disposal of discontinued operations.
ZW Data Action Technologies Inc. reported total assets of $10.68 million as of September 30, 2026, an increase from $9.68 million at the end of 2025. The company continues to navigate regulatory risks associated with the Holding Foreign Companies Accountable Act (HFCAA) due to its auditor's location in Hong Kong.
MapLight Therapeutics reported a significant increase in net loss to $172.5 million for the nine months ended September 30, 2026, compared to $81.6 million in the prior year, primarily driven by a doubling of research and development expenses. The company strengthened its balance sheet through a private placement in the third quarter of 2026, yielding $140.1 million in net proceeds.
CNS Pharmaceuticals reported a net loss of $10.0 million for the nine months ended September 30, 2026, while significantly strengthening its cash position to $17.2 million following a $22.5 million private placement in May 2026. The company is currently pivoting its corporate strategy toward acquiring new therapeutic assets and exploring out-licensing opportunities for its legacy glioblastoma programs.
FitLife Brands reported a 39.5% increase in revenue for the nine months ended September 30, 2026, reaching $77.5 million compared to $55.5 million in the prior year. Net income for the nine-month period rose to $5.24 million, driven by organic growth and the impact of the Irwin acquisition, despite higher interest expenses and selling costs.
Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.
“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Prelude Therapeutics reported a net loss of $36.9 million for the nine months ended September 30, 2026, a significant improvement from the $83.0 million loss in the prior year period, driven by a decrease in R&D expenses and $15.9 million in recognized revenue. The company strengthened its balance sheet through a $90.0 million issuance of common stock and pre-funded warrants, ending the period with $142.4 million in total current assets.
MapLight Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, including plans for its Phase 3 ZEPHYR-2 trial in schizophrenia. The company ended the quarter with $463.4 million in cash, which is expected to fund operations through 2028 and key clinical readouts.
Term
Q3 2026
“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market.”
Chris Kroeger, Co-Founder and Chief Executive Officer
“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”
Chris Kroeger, Co-Founder and Chief Executive Officer
Xtend AI Robotics reported Q3 2026 revenue of $14.9 million, a 281% year-over-year increase, driven by its AI Robotics segment. The company ended the quarter with a fully funded backlog exceeding $100 million and $66.7 million in cash following its NYSE listing and business combination with JFB Construction.
Term
Q3 2026
“Our first quarter as a public company shows our strategy is working. Revenue nearly quadrupled, nine-month revenue has already passed all of 2025, and we ended the quarter with a fully funded backlog of more than $100 million. XTEND is not just another drone company. We are a Physical AI company”
Aviv Shapira, Co-Founder and Chief Executive Officer
Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”
Carole Ben-Maimon, M.D., Chief Executive Officer
“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”
Instil Bio, Inc. reported a net loss of $13.0 million for the nine months ended September 30, 2026, a significant reduction from the $63.5 million loss in the prior year period. The company is transitioning its strategy, having discontinued its lead product candidate AXN-2510 in January 2026, and is currently seeking to in-license or acquire new therapeutic candidates.
Sativus Tech Corp. reported a net loss of $539 thousand for the nine months ended September 30, 2026, compared to $923 thousand in the prior year. The company faces substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $24.9 million and negative operating cash flows.
Venu Holding Corp reported total revenues of $14.09 million for the nine months ended September 30, 2026, a slight increase from $13.37 million in the prior year. The company experienced a significant net loss of $49.81 million during this period, driven by high general and administrative expenses and equity-based compensation. Total assets grew to $587.63 million, primarily due to a substantial increase in property and equipment related to amphitheater development.
Xtant Medical Holdings reported total assets of $75.2 million as of September 30, 2026, a decrease from $94.1 million at year-end 2025, primarily driven by a reduction in cash and the settlement of a $10.5 million note receivable. The company is currently undergoing a strategic review by its Board of Directors and recently expanded its product portfolio with the exclusive distribution of HEMOBLAST Bellows.
QVC Group, Inc. has emerged from Chapter 11 bankruptcy proceedings as of July 20, 2026, implementing a reorganization plan that includes approximately $1.3 billion in Takeback Debt and a $600 million Exit ABL Facility. The company reported 49,999,897 shares of common stock outstanding as of October 31, 2026, and is now operating under fresh start accounting which limits comparability to historical financial periods.
Barrel Energy Inc. reported a significant net loss of $1,518,216 for the nine months ended September 30, 2026, compared to a net income of $53,795 in the prior year period. The loss was primarily driven by a $1,056,653 change in the fair value of derivative liabilities and a substantial increase in operating expenses including consulting, marketing, and R&D.
Nixxy, Inc. reported a net loss of $3.88 million for the nine months ended September 30, 2026, an improvement from the $11.00 million loss in the prior year period. Revenue grew significantly to $74.51 million for the nine months, though the company continues to operate with a working capital deficit and an accumulated deficit of $117.68 million.
Invivyd, Inc. reported a significant increase in net loss to $119.3 million for the nine months ended September 30, 2026, compared to $41.4 million in the prior year, driven by a surge in R&D and SG&A expenses. Despite the higher loss, total revenue grew to $43.5 million from $36.2 million year-over-year, while cash and cash equivalents decreased to $126.4 million.
Prelude Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $142.7 million which is expected to fund operations into Q2 2028. The company advanced its clinical pipeline with the initiation of a Phase 1 study for PRT13722 in breast cancer and entered a clinical collaboration with Eli Lilly to evaluate combination therapies.
“The first three quarters of 2026 have been a period of strong execution for Prelude. We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer.”
Kris Vaddi, Ph.D., Chief Executive Officer of Prelude
Invivyd reported Q3 2026 financial results, highlighted by $15.4 million in PEMGARDA net product revenue, representing 18% year-over-year growth. The company also announced that Phase 3 clinical trial data for VYD2311 is expected imminently following regulatory dialogue with the FDA regarding accelerated approval pathways.
Term
Q3 2026
“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”
Marc Elia, Chairman and Chief Executive Officer
“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”
Lexeo Therapeutics reported total assets of $243.9 million as of September 30, 2026, a decrease from $268.7 million at year-end 2025. The company maintains a strong liquidity position with $90.2 million in cash and cash equivalents and $104.6 million in current U.S. Treasury securities to fund its ongoing clinical development of LX2006 and LX2020.
AirJoule Technologies reported Q3 2026 results, highlighting the completion of its BitSink acquisition and the delivery of its first AirJoule Prime system to a Data4 data center in France. The company also appointed Timothy N. White, an executive from Carrier Global Corporation, to its board of directors.
Term
Q3 2026
“This quarter marks an important step in AirJoule Technologies’ evolution. We expanded our commercial capabilities through the acquisition of BitSink, strengthened our market access through partnerships like Kubota, and sharpened our AirJoule product roadmap around our two highest-value platforms: Prime for water generation and Core DH for dehumidification.”
Matt Jore, Founder and Chief Executive Officer
“BitSink’s $15 million in signed purchase orders provides greater near-term revenue visibility, while our AirJoule products are moving through a more defined path to commercialization. We are deploying systems in customer environments, measuring real-world performance, and working to validate the economics that will support broader adoption.”
Xtant Medical reported Q3 2026 revenue of $24.3 million, a decrease from $33.3 million in the prior year primarily due to divested businesses and the absence of wound care licensing revenue. The company's Board of Directors also announced a formal strategic review process to evaluate operational improvements, capital structure alternatives, and potential business combinations or transactions.
Term
Q3 2026
“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable.”
Stavros Vizirgianakis, Chairman of the Board
“The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process.”